These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 7837842)

  • 1. [A new system for drug control in the EEC. Role of Sweden in an active monitoring of adverse effects].
    Wiholm BE; Beermann B; Strandberg K
    Lakartidningen; 1995 Jan; 92(3):129-32. PubMed ID: 7837842
    [No Abstract]   [Full Text] [Related]  

  • 2. [The role of the Danish Medical Products Agency in clinical trials].
    Simonsen AC
    Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center.
    Lindquist M; Edwards IR
    J Rheumatol; 2001 May; 28(5):1180-7. PubMed ID: 11361210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug reaction reporting and monitoring: role of practising physicians.
    Bhatia RS; Sibia SS
    J Assoc Physicians India; 2000 Aug; 48(8):852. PubMed ID: 11273490
    [No Abstract]   [Full Text] [Related]  

  • 5. [The incidence of drug side effects with reference to organ systems. Experience of the spontaneous reporting system of the Swiss Drug Side Effect Center and Comprehensive Drug Monitoring].
    Kuhn M; Hartmann K; Maibach R; Capaul R; Gartmann JC
    Ther Umsch; 1993 Jan; 50(1):8-12. PubMed ID: 8378869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The adverse drug reaction: a clinical opportunity for pharmacists.
    Miller JD
    Hosp Pharm; 1995 Sep; 30(9):769-73. PubMed ID: 10151281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The Medical Products Agency is responsible for the control of medical technological products: we need more active medical professionals reporting shortages].
    Philipson L
    Lakartidningen; 2008 Mar 5-11; 105(10):746-7. PubMed ID: 18422241
    [No Abstract]   [Full Text] [Related]  

  • 8. Contribution of pharmacists to the reporting of adverse drug reactions.
    van Grootheest AC; van Puijenbroek EP; de Jong-van den Berg LT
    Pharmacoepidemiol Drug Saf; 2002; 11(3):205-10. PubMed ID: 12051119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospital pharmacists' activities and attitudes regarding the Thai safety monitoring program for new drugs.
    Jarernsiripornkul N; Krska J; Pongmanachai M; Nasritha N
    Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):837-41. PubMed ID: 19548223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adverse effects of drugs in 1994. New unexpected connections were proved].
    Lakartidningen; 1995 Aug; 92(32-33):2924-5. PubMed ID: 7643712
    [No Abstract]   [Full Text] [Related]  

  • 11. Spontaneously reported fatal suspected adverse drug reactions: a 10-year survey from Sweden.
    Wester K; Jönsson A; Spigset O; Hägg S
    Pharmacoepidemiol Drug Saf; 2007 Feb; 16(2):173-80. PubMed ID: 16739241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Reporting of side-effects--a system in need of improvement. Reporting of a physician questionnaire].
    Ekbom Y; Hedenmalm K; Dalin L; Lönnroth K; Persson I
    Lakartidningen; 2002 Aug; 99(34):3290-5. PubMed ID: 12362847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacists' role in reporting adverse drug reactions in an international perspective.
    van Grootheest K; Olsson S; Couper M; de Jong-van den Berg L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):457-64. PubMed ID: 15269929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reporting rates of adverse drug reactions.
    Rich DS
    Am J Hosp Pharm; 1994 Jul; 51(13):1710-1. PubMed ID: 7942899
    [No Abstract]   [Full Text] [Related]  

  • 15. [The Medical Products Agency suggests improved drug safety follow-ups. New grasps of better knowledge and adverse effects reporting].
    Sjölin-Forsberg G; Lindeskog B; Lundqvist KM; Feltelius N; Alvan G
    Lakartidningen; 2007 Apr 18-24; 104(16):1226-9. PubMed ID: 17536352
    [No Abstract]   [Full Text] [Related]  

  • 16. [The practice of drug monitoring in the Lorraine Regional Center of Drug Monitoring (CRPV)].
    Trechot P
    Bull Soc Sci Med Grand Duche Luxemb; 1995; 132(3):41-2. PubMed ID: 8665626
    [No Abstract]   [Full Text] [Related]  

  • 17. Vaccine adverse event monitoring systems across the European Union countries: time for unifying efforts.
    Zanoni G; Berra P; Lucchi I; Ferro A; O'Flanagan D; Levy-Bruhl D; Salmaso S; Tridente G
    Vaccine; 2009 May; 27(25-26):3376-84. PubMed ID: 19200851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The GCP directive--consequences for clinical drug research].
    Gluud CN
    Ugeskr Laeger; 2003 Apr; 165(16):1662-4. PubMed ID: 12756824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reaction monitoring in India.
    Kshirsagar NA; Karande SC; Potkar CN
    J Assoc Physicians India; 1993 Jun; 41(6):374-6. PubMed ID: 8005977
    [No Abstract]   [Full Text] [Related]  

  • 20. Need for monitoring adverse drug reactions.
    Nerurkar RP; Nadkar MY; Bichile SK
    J Assoc Physicians India; 1998 Aug; 46(8):673-4. PubMed ID: 11229269
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.